• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Immunol . Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults

tetano

Editor, Senior Moderator
Sci Immunol


. 2024 Sep 2;9(92):eadj9285.
doi: 10.1126/sciimmunol.adj9285. Epub 2024 Feb 9. Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults

Helen R Wagstaffe[SUP] 1 [/SUP], Ryan S Thwaites[SUP] 2 [/SUP], Arnold Reynaldi[SUP] 3 [/SUP], Jasmin K Sidhu[SUP] 2 [/SUP], Richard McKendry[SUP] 1 [/SUP], Stephanie Ascough[SUP] 1 [/SUP], Loukas Papargyris[SUP] 1 [/SUP], Ashley M Collins[SUP] 1 [/SUP], Jiayun Xu[SUP] 1 [/SUP], Nana-Marie Lemm[SUP] 1 [/SUP], Matthew K Siggins[SUP] 2 [/SUP], Benny M Chain[SUP] 4 [/SUP], Ben Killingley[SUP] 5 [/SUP], Mariya Kalinova[SUP] 6 [/SUP], Alex Mann[SUP] 6 [/SUP], Andrew Catchpole[SUP] 6 [/SUP], Miles P Davenport[SUP] 3 [/SUP], Peter J M Openshaw[SUP] 2 [/SUP], Christopher Chiu[SUP] 1 [/SUP]



Affiliations
Abstract

Human infection challenge permits in-depth, early, and pre-symptomatic characterization of the immune response, enabling the identification of factors that are important for viral clearance. Here, we performed intranasal inoculation of 34 young adult, seronegative volunteers with a pre-Alpha severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain. Of these participants, 18 (53%) became infected and showed an interferon-dominated mediator response with divergent kinetics between nasal and systemic sites. Peripheral CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cell activation and proliferation were early and robust but showed distinct kinetic and phenotypic profiles; antigen-specific T cells were largely CD38[SUP]+[/SUP]Ki67[SUP]+[/SUP] and displayed central and effector memory phenotypes. Both mucosal and systemic antibodies became detectable around day 10, but nasal antibodies plateaued after day 14 while circulating antibodies continued to rise. Intensively granular measurements in nasal mucosa and blood allowed modeling of immune responses to primary SARS-CoV-2 infection that revealed CD8[SUP]+[/SUP] T cell responses and early mucosal IgA responses strongly associated with viral control, indicating that these mechanisms should be targeted for transmission-reducing intervention.


 
Back
Top Bottom